Lopinavir/Ritonavir

Lopinavir/Ritonavir, also known as Kaletra or Aluvia, is one of the most important HIV drugs on the market today. Yet Abbott Laboratories, the U.S. patent holder of these drugs, is not doing enough to make this important drug available to the public. Because we believe that many of the patents surrounding this essential drug are not merited, I-MAK and its partners are challenging Lopinavir/Ritonavir patents across the world.

 

INDIA REJECTS ABBOTT'S PATENT FOR KEY HIV DRUG

Press Release

Overview of Case

Fact Sheet on Abbott Laboratories and Lopinavir/Ritonavir

Doctors Without Borders Facts on Access Issues for Lopinavir/Ritonavir

HealthGap press release

MSF press release

 

Legal Documents for Opposition to Lopinavir/Ritonavir Tablet (India)

Indian Patent Office Decision (Application No. 339/MUMNP/2006)

I-MAK's Reply to Abbott

Abbott's Reply to I-MAK

I-MAK's Pre-grant Opposition

 

Legal Documents for other Oppositions against Abbott Laboratories (India)

Pre-grant Opposition to Lopinavir/Ritonavir Soft-Gel Capsule

Indian Patent Office Letter Confirming Abbott's Abandoning of Soft-Gel Capsule Application

Pre-grant Oppositon to Ritonavir Crystalline

Indian Patent Office Decision Confirming Refusal of Ritonavir Polymorph (App No. IN/PCT/2001/00018/MUM)

Pre-grant Opposition to Lopinavir Crystalline

Indian Patent Office Decision Confirming Refusal of Lopinavir Polymorph (App No. IN/PCT/2002/1243/MUM)

 

Legal Documents for Objections to Lopinavir/Ritonavir Tablet (Europe)

I-MAK Observations to the European Patent Office (25 October 2010)

I-MAK Observations to the European Patent Office (13 August 2007)

 

Related Reading

Chinese translation of documents

I-MAK Summary on Patent Oppositions to Lopinavir/Ritonavir Tablet in India and Europe

I-MAK Press Release on Patent Oppositions to Lopinavir/Ritonavir Tablet in India and Europe

I-MAK Update on EPO Lopinavir crystalline rejection

Pat(i)ent Watch fact sheet [pdf]

"Inside Abbott's Tactics to Protect AIDS Drug: Older Pill's Price Hike Helps Sales of Flagship; A Probe in Illinois", John Carreyrou, Wall Street Journal 

INP+ Discussion Paper setting out the impact of Lopinavir/Ritonavir patenting on India's treatment programme [pdf]

CP Tech page on Ritonavir

Doctors without Borders page on Lopinavir/Ritonavir

Thailand White Paper [pdf]